University Hospital Limoges
Welcome,         Profile    Billing    Logout  
 8 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ABRAHAM, Julie
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Recruiting
3
790
Europe
Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin
The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Follicular Lymphoma
11/28
04/34
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen Inc.
Diffuse Large B-cell Lymphoma
05/25
04/27
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
VERLen, NCT04974216: Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

Active, not recruiting
2
71
Europe
Tafasitamab, MOR208, Lenalidomide, Rituximab
The Lymphoma Academic Research Organisation
DLBCL
07/24
12/26
KILT, NCT04984837: Study of Lacutamab in Peripheral T-cell Lymphoma

Checkmark KIR3DL2-expressing patients with r/r PTCL
Aug 2021 - Aug 2021: KIR3DL2-expressing patients with r/r PTCL
Recruiting
2
56
Europe
Lacutamab, Gemcitabine, Oxaliplatine
The Lymphoma Academic Research Organisation, Innate Pharma
Peripheral T Cell Lymphoma, Relapse/Recurrence
01/25
01/27
OASIS-II, NCT04802590: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Recruiting
2
194
Europe
Ibrutinib 560 mg, Venetoclax 10 MG Oral Tablet [Venclexta], Venetoclax 50 MG Oral Tablet [Venclexta], Venetoclax 100 MG Oral Tablet [Venclexta]
The Lymphoma Academic Research Organisation, Institute of Cancer Research, United Kingdom
Mantle Cell Lymphoma
03/26
09/31
R-MPV, NCT04446962 / 2019-003632-23: LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin

Recruiting
1/2
118
Europe, RoW
Lenalidomide, Revlimid, Ibrutinib, Imbruvica
Institut Curie, National Cancer Institute, France
Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary
02/25
02/35
ExoReBLy, NCT03985696: Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas

Recruiting
N/A
90
Europe
blood sample
University Hospital, Limoges
Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
07/25
07/25
REALYSA, NCT03869619: REal World Data in LYmphoma and Survival in Adults

Recruiting
N/A
6000
Europe
Real-life epidemiological platform of lymphoma in France
Hospices Civils de Lyon, The Lymphoma Academic Research Organisation
Diffuse Large B Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), T-cell Lymphoma (T-NHL), Hodgkin's Lymphoma (HL), Burkitt Lymphoma (BL))
11/27
11/27
TRANSCRIPT, NCT05444712: Transplantation After Complete Response In Patients With T-cell Lymphoma

Recruiting
N/A
204
Europe
Chemotherapy + follow up, Chemotherapy + ASCT + follow up
Hospices Civils de Lyon
Peripheral T Cell Lymphoma
04/28
04/28
DESCAR-T, NCT04328298: French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment

Recruiting
N/A
5000
Europe
The Lymphoma Academic Research Organisation, Gilead Sciences, Novartis, Bristol-Myers Squibb
Hematopathology Eligible or CAR-t Cell Treatment
12/38
12/38
BONILLA, Anthony
MBI-C, NCT06516159: Validation of the Scale in French

Recruiting
N/A
170
Europe
MBI-C Scale in French
University Hospital, Toulouse
Subjective Cognitive Complaint, Mild Cognitive Impairment, Neuropsychiatric Symptoms
07/25
07/25

Download Options